Etiological treatment during early chronic indeterminate Chagas disease incites an activated status on innate and adaptive immunity associated with a type 1-modulated cytokine pattern.

[1]  A. Teixeira-Carvalho,et al.  Benznidazole Treatment during Early‐indeterminate Chagas’ Disease Shifted the Cytokine Expression by Innate and Adaptive Immunity Cells toward a Type 1‐modulated Immune Profile , 2006, Scandinavian journal of immunology.

[2]  A. Teixeira-Carvalho,et al.  Are increased frequency of macrophage‐like and natural killer (NK) cells, together with high levels of NKT and CD4+CD25high T cells balancing activated CD8+ T cells, the key to control Chagas’ disease morbidity? , 2006, Clinical and experimental immunology.

[3]  A. Teixeira-Carvalho,et al.  Chagasic Patients with Indeterminate Clinical Form of the Disease have High Frequencies of Circulating CD3+CD16–CD56+ Natural Killer T Cells and CD4+CD25High Regulatory T Lymphocytes , 2005, Scandinavian journal of immunology.

[4]  A. C. Campos-de-Carvalho,et al.  Treatment with Benznidazole during the Chronic Phase of Experimental Chagas' Disease Decreases Cardiac Alterations , 2005, Antimicrobial Agents and Chemotherapy.

[5]  F. Sánchez‐Madrid,et al.  CD69 is an immunoregulatory molecule induced following activation. , 2005, Trends in immunology.

[6]  O. Bottasso,et al.  Benznidazole, a drug used in Chagas' disease, ameliorates LPS-induced inflammatory response in mice. , 2004, Life sciences.

[7]  A. Teixeira-Carvalho,et al.  Phenotypic Features of Peripheral Blood Leucocytes During Early Stages of Human Infection with Trypanosoma cruzi , 2003, Scandinavian journal of immunology.

[8]  R. Corrêa-Oliveira,et al.  Evidence that Development of Severe Cardiomyopathy in Human Chagas' Disease Is Due to a Th1-Specific Immune Response , 2003, Infection and Immunity.

[9]  T. Araújo-Jorge,et al.  Benznidazole Treatment following Acute Trypanosoma cruzi Infection Triggers CD8+ T-Cell Expansion and Promotes Resistance to Reinfection , 2002, Antimicrobial Agents and Chemotherapy.

[10]  T. Espevik,et al.  The Proinflammatory CD14+CD16+DR++ Monocytes Are a Major Source of TNF1 , 2002, The Journal of Immunology.

[11]  J. Urbina.  Chemotherapy of Chagas disease. , 2002, Current pharmaceutical design.

[12]  J. Coura,et al.  A critical review on Chagas disease chemotherapy. , 2002 .

[13]  R. Corrêa-Oliveira,et al.  Immunological and clinical evaluation of chagasic patients subjected to chemotherapy during the acute phase of Trypanosoma cruzi infection 14-30 years ago. , 2000, The Journal of infectious diseases.

[14]  L. Galvão,et al.  Chagas disease: criteria of cure and prognosis. , 1999, Memorias do Instituto Oswaldo Cruz.

[15]  J. Urbina.  Chemotherapy of Chagas’ disease: the how and the why , 1999, Journal of Molecular Medicine.

[16]  A. Rassi,et al.  [Treatment of chronic Chagas' disease. Is the etiological treatment effective?]. , 1998, Arquivos Brasileiros de Cardiologia.

[17]  R. Gazzinelli,et al.  Interleukin-12 Enhances In Vivo Parasiticidal Effect of Benznidazole during Acute Experimental Infection with a Naturally Drug-Resistant Strain of Trypanosoma cruzi , 1998, Antimicrobial Agents and Chemotherapy.

[18]  E. Segura,et al.  Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. , 1998, The American journal of tropical medicine and hygiene.

[19]  R. Gazzinelli,et al.  Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas' disease. , 1997, International archives of allergy and immunology.

[20]  Simonne Almeida e Silva,et al.  Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection , 1996, The Lancet.

[21]  W. Dutra,et al.  Influence of parasite presence on the immunologic profile of peripheral blood mononuclear cells from chagasic patients after specific drug therapy , 1996, Parasite immunology.

[22]  H. Ziegler-Heitbrock,et al.  Heterogeneity of human blood monocytes: the CD14+ CD16+ subpopulation. , 1996, Immunology today.

[23]  O. Martins-Filho,et al.  Activated T and B lymphocytes in peripheral blood of patients with Chagas' disease. , 1994, International immunology.

[24]  E. Segura,et al.  Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. , 1994, American heart journal.

[25]  F. Sánchez‐Madrid,et al.  Upregulated expression and function of VLA-4 fibronectin receptors on human activated T cells in rheumatoid arthritis. , 1991, The Journal of clinical investigation.

[26]  S. G. Andrade,et al.  Experimental chemotherapy of Trypanosoma cruzi infection: persistence of parasite antigens and positive serology in parasitologically cured mice. , 1991, Bulletin of the World Health Organization.